IMMURON LTD/ AU000000IMC7 /

2/7/2023 8:31:48 AM	Chg. -0.0010	Volume	Bid2:05:45 PM	Ask2:05:45 PM	High	Low
0.0490EUR	-2.00%	0 Turnover: 0.0000	-Bid Size: -	-Ask Size: -	0.0490	0.0490

GlobeNewswire 3/16/2022 Appointment of Paul Brennan as Non-Executive Director

GlobeNewswire 1/17/2022 Immuron Receives AUD $306,154 R&D Tax Concession Refund

GlobeNewswire 1/13/2022 Immuron Receives European Patent on Drug Composition to Treat Travelers’ Diarrhea

GlobeNewswire 11/15/2021 US DoD Uniformed Services University Travelers’ Diarrhea Clinical Update

GlobeNewswire 11/10/2021 US DoD Naval Medical Research Center Clinical Update

GlobeNewswire 10/8/2021 IMM-124E – Demonstrates Antiviral T-Cell Immunity

GlobeNewswire 9/24/2021 Immuron Director resignation

GlobeNewswire 9/23/2021 Immuron planned Acquisition of R&D Vaccine Company

GlobeNewswire 5/13/2021 IMM124E – May offer a New modality for Inhibition of SARS-CoV-2

GlobeNewswire 1/11/2021 Immuron to Participate in H.C. Wainwright & Co. BioConnect 2021 Virtual Conference

GlobeNewswire 12/15/2020 Immuron SARS-CoV-2 Research Agreement with Monash University

GlobeNewswire 11/24/2020 Immuron Receives AUD $358,280 R&D Tax Concession Refund

GlobeNewswire 11/11/2020 US DoD Naval Medical Research Center Reports Positive Immunological Responses to Vaccine

GlobeNewswire 10/12/2020 Immuron Travelers’ Diarrhea Market Update

GlobeNewswire 7/23/2020 Immuron Limited Announces Closing of $20.0 Million Registered Direct Offering

GlobeNewswire 7/21/2020 Immuron Announces $20.0 Million Registered Direct Offering

GlobeNewswire 7/21/2020 Immuron Reports Neutralizing Activity Against SARS-CoV-2 Key Points

GlobeNewswire 7/20/2020 US DoD Naval Medical Research Center Receives FDA Guidance on the clinical development plans for new...

GlobeNewswire 6/19/2020 Immuron Partners with CSIRO to produce a new oral therapeutic for clinical evaluation by the US Depa...

GlobeNewswire 6/9/2020 US DoD Naval Medical Research Center Requests Meeting with FDA for Guidance on two Phase 2 trials to...

GlobeNewswire 4/28/2020 Immuron Board Relinquish Cash Payment of Fees

GlobeNewswire 4/20/2020 Immuron North American Travelan® Sales Up 95%, Global Sales Up 60%

GlobeNewswire 3/25/2020 Resignation of CEO & Director and cost cutting amidst COVID-19

GlobeNewswire 3/3/2020 Immuron Provides Update on First Half of FY20 Results

GlobeNewswire 2/3/2020 Immuron’s Technology Platform of Treatments in the Age of the Coronavirus Outbreak